The US patent is a major cornerstone in the strategy to further protect SynAct’s intellectual property rights with respect to resomelagon and will add to the layers of protection ensuring exclusivity in the US of its lead asset as composition of matter until 2042, it states.

“We are thrilled by this news which supports that we have laid out a successful patent strategy for resomelagon. A composition of matter patent for a crystal form of a drug candidate will apply irrespective of how the claimed solid is formulated or used, and thus it is a very broad and strong patent,” says Thomas Boesen, COO at SynAct.

Resomelagon

Resomelagon, currently in Phase 2b clinical development in Rheumatoid Arthritis, is administered in a specific salt form. During the development of the drug candidate, SynAct prepared a crystal form of this specific salt and discovered associated favorable properties. The patent that has now issued by the USPTO is the first in its extended family of patent applications in all major markets around the globe. SynAct continues to pursue additional patent families to further enhance its existing patent estate protecting aspects of resomelagon.